1055 related articles for article (PubMed ID: 32113509)
1. COVID-19: combining antiviral and anti-inflammatory treatments.
Stebbing J; Phelan A; Griffin I; Tucker C; Oechsle O; Smith D; Richardson P
Lancet Infect Dis; 2020 Apr; 20(4):400-402. PubMed ID: 32113509
[No Abstract] [Full Text] [Related]
2. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Richardson P; Griffin I; Tucker C; Smith D; Oechsle O; Phelan A; Rawling M; Savory E; Stebbing J
Lancet; 2020 Feb; 395(10223):e30-e31. PubMed ID: 32032529
[No Abstract] [Full Text] [Related]
3. COVID-19: an unexpected indication for anti-rheumatic therapies?
Lucchino B; Di Franco M; Conti F
Rheumatology (Oxford); 2020 Jun; 59(6):1200-1203. PubMed ID: 32374874
[No Abstract] [Full Text] [Related]
4. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
Spinelli FR; Conti F; Gadina M
Sci Immunol; 2020 May; 5(47):. PubMed ID: 32385052
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Stebbing J; Krishnan V; de Bono S; Ottaviani S; Casalini G; Richardson PJ; Monteil V; Lauschke VM; Mirazimi A; Youhanna S; Tan YJ; Baldanti F; Sarasini A; Terres JAR; Nickoloff BJ; Higgs RE; Rocha G; Byers NL; Schlichting DE; Nirula A; Cardoso A; Corbellino M;
EMBO Mol Med; 2020 Aug; 12(8):e12697. PubMed ID: 32473600
[TBL] [Abstract][Full Text] [Related]
6. [Baricitinib in the treatment of SARS-CoV-2 infection].
Gutiérrez-Lorenzo M; Cuadros-Martínez CM
Rev Esp Quimioter; 2020 Aug; 33(4):294-295. PubMed ID: 32583654
[No Abstract] [Full Text] [Related]
7. Baricitinib for COVID-19: a suitable treatment?
Favalli EG; Biggioggero M; Maioli G; Caporali R
Lancet Infect Dis; 2020 Sep; 20(9):1012-1013. PubMed ID: 32251638
[No Abstract] [Full Text] [Related]
8. Baricitinib for COVID-19: a suitable treatment? - Authors' reply.
Richardson PJ; Corbellino M; Stebbing J
Lancet Infect Dis; 2020 Sep; 20(9):1013-1014. PubMed ID: 32251639
[No Abstract] [Full Text] [Related]
9. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
Cingolani A; Tummolo AM; Montemurro G; Gremese E; Larosa L; Cipriani MC; Pasciuto G; Liperoti R; Murri R; Pirronti T; Cauda R; Fantoni M;
Infection; 2020 Oct; 48(5):767-771. PubMed ID: 32642806
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
Praveen D; Puvvada RC; M VA
Int J Antimicrob Agents; 2020 May; 55(5):105967. PubMed ID: 32259575
[TBL] [Abstract][Full Text] [Related]
11. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Barlow A; Landolf KM; Barlow B; Yeung SYA; Heavner JJ; Claassen CW; Heavner MS
Pharmacotherapy; 2020 May; 40(5):416-437. PubMed ID: 32259313
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
[TBL] [Abstract][Full Text] [Related]
13. Prescribing COVID-19 treatments: what we should never forget.
Tunesi S; Bourgarit A
J Infect; 2020 Aug; 81(2):e85. PubMed ID: 32405110
[No Abstract] [Full Text] [Related]
14. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
15. Principles of Care for Patients with Liver Disease During the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation.
Alqahtani SA; Aljumah AA; Hashim A; Alenazi TH; AlJawad M; Al Hamoudi WK; Alghamdi MY
Ann Saudi Med; 2020; 40(4):273-280. PubMed ID: 32564624
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
Jorgensen SCJ; Tse CLY; Burry L; Dresser LD
Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785
[TBL] [Abstract][Full Text] [Related]
17. The type I interferon response in COVID-19: implications for treatment.
Lee JS; Shin EC
Nat Rev Immunol; 2020 Oct; 20(10):585-586. PubMed ID: 32788708
[TBL] [Abstract][Full Text] [Related]
18. Erythema multiforme in the context of SARS-Coronavirus-2 infection.
Sánchez-Velázquez A; Falkenhain D; Rivera Díaz R
Med Clin (Barc); 2020 Aug; 155(3):141. PubMed ID: 32475615
[No Abstract] [Full Text] [Related]
19. Treatments for COVID-19: where are we now?
Mendes A
Br J Community Nurs; 2020 Aug; 25(8):412-413. PubMed ID: 32757900
[No Abstract] [Full Text] [Related]
20. COVID-19 revisiting inflammatory pathways of arthritis.
Schett G; Manger B; Simon D; Caporali R
Nat Rev Rheumatol; 2020 Aug; 16(8):465-470. PubMed ID: 32561873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
